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Background
Insight into factors associated with outcomes of meth-
otrexate (MTX) treatment may contribute to more individ-
ualized treatment of juvenile idiopathic arthritis (JIA). In
this study, associations of SNPs in genes encoding folate
pathway enzymes with MTX efficacy and adverse effects in
JIA patients were evaluated.
Methods
Genotypes were determined in an observational cohort of
183 JIA patients that had been systematically followed at
3 months intervals. The following SNPs were determined:
methylenetetrahydrofolate reductase (MTHFR) 677C>T
and 1298A>C, methionine synthase reductase (MTRR)
66A>G, thymidylate synthase (TS) 2R/3R and Reduced
Folate Carrier (RFC) 80G>A. MTX efficacy and adverse
effects were compared among genotypes during the first
year of treatment and at long-term follow up.
Results
The MTHFR 1298CC variant was associated with MTX
efficacy (OR 3.3, 95%-CI 1.0–10.2) after 3 months, while
MTHFR 677T-allele carriers had a lower chance of early
good clinical response (OR 0.4, 95%-CI 0.2–0.9). The
MTHFR 1298C-allele was also associated with MTX effi-
cacy after long-term follow-up (OR 1.8, 95%-CI 1.0–3.4).
Regarding adverse effects, MTHFR 677TT was associated
with liver toxicity in the first year of MTX use (OR 10.4,
95%-CI 2.2–48.6). MTRR 66G-allele carriers were more
likely to have gastrointestinal intolerance during the first
3 months of treatment (OR 9.9, 95%-CI 1.3–76.9).
Conclusion
Polymorphisms in the MTHFR and MTRR genes are asso-
ciated with methotrexate efficacy and adverse effects. Gen-
otyping may add in predicting response to MTX treatment
in JIA patients.
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